Table 3 Clinical assessment of chronic GVHD
From: Graft versus host disease-related eosinophilic fasciitis: cohort description and literature review
GROUP 1 fasciitis absent | GROUP 2 fasciitis present | p | |
|---|---|---|---|
Variables | N (%)/media (DS) | N (%)/media (DS) | |
Total, n | 43 | 39 | |
Time in months from allo-HCT to enrollment (range) | 20 (4–175) | 17 (6–66) | 0.480 |
cGVHD type | |||
Progressive/quiescent/de novo | 8 (18.6%)/22 (51.2%) /13 (30.2%) | 7 (18.0%)/20 (51.2%) /12 (30.8%) | Ns |
Involvement site | |||
ECOG: 1/2/3 | 14 (32.6%)/6 (14.0%)/2 (4.7%) | 16 (41.0%)/6 (15.4%)/0 | 0.500 |
Mouth | 15 (34.8%) | 18 (46.2%) | 0.415 |
Eye | 21 (48.8%) | 18 (46.2%) | 0.466 |
Genital tract | 3 (6.9%) | 4 (10.3%) | 0.405 |
Gastrointestinal | 3 (6.9%) | 2 (5.2%) | 0.382 |
Liver | 10 (23.2%) | 7 (18.0%) | 0.384 |
Lung | 3 (6.9%) | 5 (12.8%) | 0.640 |
Skin | 32 (74.4%) | 35 (89.7%) | 0.000 |
NIH global score | |||
Moderate/severe | 26 (60.5%)/17 (39.5%) | 0/39 (100%) | 0.000 |
Bone complications | |||
Avascular osteonecrosis/bone fracture | 3 (6.9%) | 3 (7.8%) | ns |